TPI Receives SFDA Approval for Its Anti-Diabetic Drug Gliclazide

Tianyin Pharmaceutical TPI today announced that TPI has received the China's SFDA's approval for its anti-diabetic drug Gliclazide Tablets (80 mg formulation). Gliclazide is an oral anti-diabetic drug that is used for the control of hyperglycemia in gliclazide-response diabetes mellitus of stable, mild, non-ketosis prone, maturity-onset. It is used when diabetes could not be managed by proper dietary adjustment and exercise or when not suitable for insulin therapy. TPI is anticipating that its Gliclazide Tablets to make its market entry in July this year.